This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join our CPD accredited meeting 'Introducing ELREXFIO®▼ (elranatamab), a new BCMA-directed Bispecific Immunotherapy' on Tuesday 5th November 2024, with Professor Graham Jackson and Dr Jaimal Kothari, as they explore the outcomes and unmet needs for patients with RRMM, including those with TCE disease, examining elranatamab’s efficacy and safety profile, key considerations around dosing and administration and discussing educational hypothetical patient case studies. The presentation will be followed by a live interactive Q&A.
This is a hybrid meeting, giving you the opportunity to attend in-person (Sheffield) or virtually. Please register your interest to attend and further information will be sent to you.
Elrexfio® is now recommended by NICE.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
Prescribing information can be found at the bottom of the page.
Join our CPD accredited meeting 'Introducing ELREXFIO®▼ (elranatamab), a new BCMA-directed Bispecific Immunotherapy' on Tuesday 5th November 2024, with Professor Graham Jackson and Dr Jaimal Kothari, as they explore the outcomes and unmet needs for patients with RRMM, including those with TCE disease, examining elranatamab’s efficacy and safety profile, key considerations around dosing and administration and discussing educational hypothetical patient case studies. The presentation will be followed by a live interactive Q&A.
This is a hybrid meeting, giving you the opportunity to attend in-person (Sheffield) or virtually. Please register your interest to attend and further information will be sent to you.
Elrexfio® is now recommended by NICE.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and may include reference to medicines or vaccines promoted by Pfizer.
Dr Graham Jackson is Professor of Clinical Haematology at Newcastle University and Consultant Haematologist at Newcastle Upon Tyne Hospitals Trust. Dr Jackson graduated from Cambridge and the Westminster School of Medicine, and completed his MRCP in 1986 and MD in 1992 at Newcastle University. Dr Jackson obtained his MRCPath in 1993, FRCP in 1999, and FRCPath in 2000. Dr Jackson's notable awards include the Mortimer M Bortin Award (1995), the Van Bekkum Medal (2004), and the BSH Gold Medal (2015).
Dr Jackson has served as president of the BSH and BSBMT, and on the RCPath council, CRUK CTAAC, and Bloodwise clinical trials committee. Dr Jackson has directed Myeloma UK, been scientific secretary for the UKMF, and is a chief investigator for multiple MRC Myeloma trials. Dr Jackson has been CI on the MRC Myeloma 9, 11 and 11+ and is currently the co-CI for myeloma 14. Dr Jackson is part of the safety monitoring committee for all the MUK trials as well as several International studies.
Dr Jackson's research focuses on myeloma treatment trials and safety, and he is committed to doctor-patient communication.
Dr Jackson has published over 240 peer-reviewed papers and numerous book chapters.
Dr Jaimal Kothari is a consultant haematologist at Oxford University Hospitals, and clinical lead for Myeloma for Oxford and Thames Valley. Dr Kothari did his Haematology training at UCLH, before joining the Consultant Group in Oxford in 2014. As well as myeloma, Dr Kothari has an interest in Waldenstrom Macroglobulinaemia and has led numerous clinical trials in both.
Elrexfio®▼(elranatamab)
ELREXFIO® (elranatamab) has a conditioning marketing authorisation. A conditional marketing authorisation means that further evidence of efficacy and safety data are being collected. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year.
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024